Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical companies, including the makers of Xarelto, possess a duty to make sure that their drugs are reasonably protected for use – and failure to complete so may be grounds for compensation. Our lawyers are working tough to obtain these hurt by the drug the compensation they’re entitled to.
Whilst bleeding is a widespread complication linked with anticoagulants, it has been alleged that Xarelto is a lot more hazardous than classic blood thinners since no antidote exists to reverse its blood-thinning effects. This indicates that, inside the occasion of an emergency, sufferers could be at risk for irreversible bleeding difficulties, such as life-threatening internal and gastrointestinal hemorrhaging.
In the event you or sneak a peek at these guys loved one suffered a critical bleeding event following taking Xarelto, you might have legal recourse. For more information, contact us these days to possess your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future healthcare bills, lost wages, discomfort and suffering and, in situations of death, funeral expenditures. Moreover, they may be looking for punitive damages, that are usually awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding in the occasion of an emergency. Plaintiffs in the lawsuits allege critical and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.
Visit this page for far more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.